Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.YOSEMITE and RHINE Investigators*(Menteş J, in Yosemite Study Group) | AVESİS

Ege University Research Information System

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.YOSEMITE and RHINE Investigators*(Menteş J, in Yosemite Study Group)

Lancet, vol.339, no.10326, pp.741-755, 2022 (Journal Indexed in SCI Expanded)

Publication Type: Article / Article
Volume: 339 Issue: 10326
Publication Date: 2022
Doi Number: 10.1016/s0140-6736(22)00018-6
Title of Journal : Lancet
Page Numbers: pp.741-755